Drugmakers are taking legal action against a new federal pilot program designed to link Medicare drug prices to those in other wealthy nations, arguing the initiative could undermine innovation and patient access. The Pharmaceutical Research and Manufacturers of America filed a lawsuit, contending the approach risks imposing foreign pricing models on the U.S. market without sufficient safeguards. Critics of the program say it could lead to lower drug costs for seniors, while supporters warn of potential disruptions to research and development. The legal challenge sets up a clash between cost-control measures and industry concerns over market stability.
Click in for more news from The Hill {beacon} Healthcare Healthcare The Big Story PhRMA sues over drug pricing pilot Drugmakers are challenging a new Trump administration pilot program tying Medicare drug prices to those in other wealthy countries. © AP Photo/John Hanna The Pharmaceutical Research and Manufacturers of America alleged in the...
